CNS Therapeutics Xchange
- Non-invasive approaches
- Revisiting old biomarkers with new approaches
- Patient identification/stratification
- Defining neuroinflammation
Vice President, Translational Biology
Jonathan Levenson is the Vice President of Translational Biology at Tiaki Therapeutics. Prior to joining Tiaki, he was the head of preclinical and nonclinical research and development at Proclara where he was key in moving two assets into the clinic, one for Alzheimer’s disease and one for systemic amyloidosis. Before that, Jonathan worked at Galenea where he held positions of increasing responsibility, culminating in the role of senior scientist. Jonathan was an assistant professor and the director of the rodent behavioral core at the University of Wisconsin-Madison. He was previously a consultant at Saegis Pharmaceuticals and an assistant professor at Baylor College of Medicine. He earned his doctorate in Biology from the University of Houston and did his post-doctoral training at the Baylor College of Medicine in the Department of Neuroscience. He has authored or co-authored over 70 research publications focused on neuropharmacology and the treatment of neurological diseases.
- What are the current best CNS therapeutics biomarkers, and how many degrees of separation is there between readout and known clinical manifestation? Can we learn from the success stories?
- How can we as a field collect data to support direct links between biomarkers and outcome?
- What technologies are currently believable in accelerating CNS therapeutics?
Director, Scientific Strategy & Business Development
Thomas received his PhD in cancer biology, focusing one cell cycle and transcription regulation, from the University of Helsinki Medical School in Finland. He completed a post-doctoral EMBO fellowship at the Dana Farber Cancer Institute in Boston, researching the genomics of breast and prostate cancer. Tom joined Aiforia to advance the new potential of cancer biology, pathology, big data, and artificial intelligence. At Aiforia Tom works with advanced Pharma and Clinical Projects Customers to bring the newest tools and solutions to the forefront of diagnosis, and therapeutics research and Development.
1:00pm – 2:00pm
- Moving away from the classical “one-size-fits-all” approach towards more “molecularly” tailored therapy for truly effective CNS treatment options
- Generating an “omic” profile using powerful methods for characterizing patients (proteomics, metabolomics, genomics)
- Risk Assessment for Neurodegenerative and Neurodevelopmental Disorders Utilizing Polygenic Scores
- Biomarkers for identifying and tracking patients – Fluid biomarkers for CNS-specific proteins (blood, CSF) and digital biomarkers (wearable sensor devices) could have the most impact in monitoring CNS diseases
- Could CNS drugs achieve the same success as cancer drugs in gaining approval in biomarker defined (guided) subgroups?
Chief Medical Officer
As Chief Medical Officer Dr. Ticho is responsible for Stoke’s efforts to develop first-in-class RNA based disease-modifying medicines to treat severe neurologic genetic diseases. Prior to joining Stoke Barry was Head of R&D for Cardiovascular and Metabolic Diseases at Moderna Therapeutics. He was previously Head of External R&D Innovation for Cardiovascular and Metabolic Diseases at Pfizer. Prior to that he was Vice President of Clinical Development at Biogen where he led clinical development for the Tysabri program for MS and led the aducanumab program for Alzheimer’s Disease. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago and completed Pediatrics training at Northwestern University and a Cardiology fellowship at Children’s Hospital in Boston. He was on clinical staff at Harvard Medical School and Massachusetts General Hospital.
4:15pm – 4:45pm
Closing Keynote & Address: